Story perspectives

Sam Altman Backs Startup to Eradicate Hereditary Diseases

11/15/2025

50 12

Summary

Story summary

Sam Altman, OpenAI CEO, is investing in Preventive, a startup aiming to eliminate hereditary diseases in babies.
Preventive has raised $30 million and is exploring jurisdictions, with the United Arab Emirates identified as a potential option.
Ethical concerns remain about applying genetic editing to humans, including risks of unforeseen mutations and eugenics.
Recent gene editing advances have yielded treatments for newborns with severe genetic conditions, prompting calls for broader regulatory approval.

1 of 1

Story summary

Sam Altman, OpenAI CEO, is investing in Preventive, a startup aiming to eliminate hereditary diseases in babies.
Preventive has raised $30 million and is exploring jurisdictions, with the United Arab Emirates identified as a potential option.
Ethical concerns remain about applying genetic editing to humans, including risks of unforeseen mutations and eugenics.
Recent gene editing advances have yielded treatments for newborns with severe genetic conditions, prompting calls for broader regulatory approval.